Filtered By:
Condition: Peripheral Vascular Disease (PVD)
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 2060 results found since Jan 2013.
Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions
Kardiol Pol. 2023 Jul 25. doi: 10.33963/KP.a2023.0162. Online ahead of print.ABSTRACTCardiovascular diseases account for 43% of deaths in Poland. The COVID-19 pandemic increased the number of cardiovascular deaths by as much as 16.7%. Lipid metabolism disorders are observed in about 20 million Poles. Lipid disorders are usually asymptomatic, they cause a significant increase in the risk of cardiovascular diseases. Up to 20% of patients who experience an acute coronary syndrome (ACS) may experience a recurrence of a cardiovascular event within a year, and up to 40% of these patients may be re-hospitalized. Within 5 years af...
Source: Kardiologia Polska - July 25, 2023 Category: Cardiology Authors: Przemys ław Mitkowski Adam Witkowski Janina St ępińska Maciej Banach Piotr Jankowski Mariusz G ąsior Krystian Wita Stanis ław Bartuś Pawe ł Burchardt Micha ł M Farkowski Marek Gierlotka Robert Gil Przemys ław Leszek Maciej Sterli ński Piotr Szym Source Type: research
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news
Focus on Prevention: Peripheral Arterial Disease and the Central Role of the Cardiologist
J Clin Med. 2023 Jun 28;12(13):4338. doi: 10.3390/jcm12134338.ABSTRACTPeripheral artery disease (PAD) is a manifestation of systemic atherosclerotic disease. PAD patients have a poor prognosis with an increased risk of cardiovascular (CV) events, including myocardial infarction (MI), stroke, limb ischemia and CV death; therefore, it is important to detect and treat PAD early. PAD and coronary artery disease (CAD) share a common pathogenesis and risk factors for development; therefore, cardiologists are in a unique position to screen, diagnosis and treat PAD. Moreover, PAD and CAD also share some treatment goals, including ...
Source: Atherosclerosis - July 14, 2023 Category: Cardiology Authors: Vincenzo Fioretti Donato Gerardi Giuseppe Giugliano Aldo Di Fazio Eugenio Stabile Source Type: research
Associations of Tissue and Soluble LOX-1 with Human Abdominal Aortic Aneurysm
Conclusions In AAA, sLOX-1 was differently affected by age, cardiometabolic diseases, and corresponding medical therapies. Comparison with nonatherosclerotic disease would be beneficial to further elucidate the diagnostic potential of sLOX-1, although it was not useful for risk stratification. Aneurysmal LOX-1 mRNA expression was increased and positively associated with smooth muscle cells and collagen content, suggesting that LOX-1 is eventually not deleterious in human AAA and could counteract AAA rupture.PMID:37421287 | DOI:10.1161/JAHA.122.027537
Source: Atherosclerosis - July 8, 2023 Category: Cardiology Authors: Anja Hofmann Yazan Khorzom Anna Klimova Steffen Wolk Albert Busch Pamela Sabarstinski Margarete M üglich Dmitry Egorov Irakli Kopaliani David M Poitz Marvin Kapalla Bianca Hamann Frieda Frank Christian J änichen Coy Brunssen Henning Morawietz Christian Source Type: research
Risk factors for cardiovascular disease in primary Sj ögren’s syndrome (pSS): a 20-year follow-up study
ConclusionsExtraglandular involvement was associated with a higher prevalence of arterial hypertension, dyslipidemia, hyperuricemia, and coronary artery disease. Anti-Ro/SSA and anti-La/SSB seropositivity was associated with a higher prevalence of cardiac rhythm abnormalities, hyperuricemia, venous thrombosis, coronary artery disease, and cerebrovascular disease. Raised inflammatory markers, disease activity measured by ESSDAI, extraglandular involvement, serologic markers including hypergammaglobulinemia and low C3, and treatment with corticosteroids were associated with a higher risk for cardiovascular comorbidities.Key ...
Source: Clinical Rheumatology - July 4, 2023 Category: Rheumatology Source Type: research
